A real report — anonymised — from a real panel. 22 biomarkers. Four body systems. Plain-English interpretation, trend analysis, and prioritised next steps.
Three of your four liver markers are in range and have been steady. The fourth, ALT, has moved upward across each of your last three tests — a slow, consistent direction that's now placed it just above the upper reference limit of 35 U/L. Caught at this stage and isolated to a single enzyme, the most common drivers respond well to lifestyle change.
The shape of the trajectory matters more than the value itself. December's reading (32) was unremarkable. February's (43) was borderline. April's (48) is the third consecutive move in the same direction — the threshold at which mild ALT elevation moves from "noted" to "investigate the trend."
Strong, sustained improvement across the whole panel. LDL has continued downward to 102 mg/dL, comfortably within the optimal range and meaningfully below where it sat a year ago (116). Triglycerides have followed the same trajectory. HDL is inching upward — a genuinely good sign.
The most likely driver, based on the interventions log, is the dietary change made in August 2025 — reduced refined carbohydrate, more fish. The pattern across four panels is consistent enough to attribute the improvement to that change with reasonable confidence.
All four metabolic markers are within reference ranges, but they're sitting toward the higher end of normal — and have been across the last two tests. HbA1c at 5.5% and fasting glucose at 92 mg/dL are both technically "normal", but in optimal ranges, both sit borderline. Fasting insulin and HOMA-IR tell a similar story: in range, drifting upward.
This is the kind of pattern that wouldn't appear on a single test — none of these values trip a clinical threshold individually. It only becomes visible when looking at a sequence. It's worth monitoring because it overlaps with the early-NAFLD picture suggested by the liver enzyme drift.
All three thyroid markers are solidly within target ranges and have been stable across every test in the history. TSH at 2.1 mIU/L sits comfortably mid-range. Free T3 and Free T4 are in good balance. Nothing to flag and nothing to change here — this panel is well-managed.
Biomarkers don't work in isolation. Biomarkr identifies connections across systems that may only be visible when reading the full picture together.
The slow upward drift in ALT (liver) and the parallel upward drift in HbA1c, fasting glucose and HOMA-IR (metabolic) are telling a consistent story. Each system individually is within or near range — but together, the direction of travel is worth paying attention to.
Early NAFLD and early metabolic dysfunction frequently co-present with exactly this pattern: no single alarming value, but a gentle drift in the same direction across two linked systems. The good news is that the interventions that help one system tend to help both. Reducing refined carbohydrates, increasing movement, and reducing alcohol — the same actions recommended for the liver — also address early insulin resistance.
The improvement across five cardiovascular markers — LDL, HDL, total cholesterol, triglycerides, ApoB — aligns closely with the dietary intervention logged in August 2025. The timing, magnitude, and cross-marker consistency make this attribution more than coincidental.
This is biomarkr doing what it's designed to do: connecting the lifestyle change logged in April to the result visible now. Without longitudinal tracking, this improvement would appear in isolation — a good result with no clear reason. With the history, it becomes evidence that the intervention worked.
Prioritised by clinical urgency. These are discussion points, not prescriptions — talk to your GP if anything concerns you.